Astera Labs (ALAB) counsel sells 10,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Astera Labs, Inc. General Counsel and Secretary Philip Mazzara reported open-market sales of 10,000 shares of common stock on March 2, 2026. The transactions were carried out in multiple tranches at weighted average prices ranging from about $113.37 to $120.99 per share.

The filing notes that all sales occurred automatically under a pre-established Rule 10b5-1 trading plan adopted on May 29, 2025, which is designed to systematically execute trades over time. Following these sales, Mazzara directly owns 128,084 shares of Astera Labs common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazzara Philip

(Last) (First) (Middle)

C/O ASTERA LABS, INC.

2345 NORTH FIRST STREET

(Street)

SAN JOSE CA 95131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Astera Labs, Inc. [ ALAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		1,200	D	$113.847(2)	136,884	D
Common Stock	03/02/2026		S(1)		677	D	$114.8149(3)	136,207	D
Common Stock	03/02/2026		S(1)		750	D	$115.8424(4)	135,457	D
Common Stock	03/02/2026		S(1)		1,205	D	$116.8454(5)	134,252	D
Common Stock	03/02/2026		S(1)		3,200	D	$117.9196(6)	131,052	D
Common Stock	03/02/2026		S(1)		1,202	D	$118.8862(7)	129,850	D
Common Stock	03/02/2026		S(1)		1,566	D	$120.2261(8)	128,284	D
Common Stock	03/02/2026		S(1)		200	D	$120.98(9)	128,084	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $113.3700 to $114.1600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $114.4400 to $115.1800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $115.4500 to $116.3700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $116.4500 to $117.2100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.4700 to $118.2600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $118.4900 to $119.4700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $119.7300 to $120.5700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $120.9700 to $120.9900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Philip Mazzara	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Astera Labs (ALAB) insider Philip Mazzara report in this Form 4?

Astera Labs General Counsel Philip Mazzara reported selling 10,000 shares of common stock in open-market transactions. The trades occurred on March 2, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted in May 2025.

How many Astera Labs (ALAB) shares did Philip Mazzara sell and at what prices?

Philip Mazzara sold a total of 10,000 Astera Labs common shares across multiple trades. Weighted average sale prices for the tranches ranged from about $113.37 to $120.99 per share, as disclosed in the detailed price-range footnotes.

Does Philip Mazzara still hold Astera Labs (ALAB) shares after these sales?

Yes. After completing the 10,000-share sale, Philip Mazzara directly holds 128,084 shares of Astera Labs common stock. This remaining balance reflects his updated ownership position following the March 2, 2026 transactions reported in the Form 4.

Were the Astera Labs (ALAB) insider sales part of a Rule 10b5-1 plan?

Yes. The filing states the sales occurred automatically under a Rule 10b5-1 trading plan adopted by Philip Mazzara on May 29, 2025. Such plans pre-schedule trades, helping insiders diversify holdings while reducing concerns about trading on nonpublic information.

What role does Philip Mazzara hold at Astera Labs (ALAB)?

Philip Mazzara serves as General Counsel and Secretary at Astera Labs. As a senior executive officer, his equity transactions in company stock must be reported on Form 4, providing public transparency into his ownership changes and trading activity.

What type of transactions did Astera Labs (ALAB) report for Philip Mazzara?

The Form 4 reports open-market sales of common stock, coded as “S” transactions. Each sale represents a non-derivative disposition of Astera Labs shares directly owned by Philip Mazzara, executed at various weighted average prices on March 2, 2026.